Navigation Links
EntreMed Raises $20 Million to Support Clinical Development Program
Date:9/17/2007

cal trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and cli
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
9. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
10. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, Inc. ... webcast:What: , Webcast and conference call to provide ... clinical studies of ISIS-SMN Rx in infants ... will be presented on the morning (CEST) of ... Muscle Society in Berlin, GermanyWhen:Friday, October 10 at ...
(Date:10/2/2014)... Ireland , Oct. 2, 2014   West ... a global leader in innovative solutions for injectable drug ... manufacturing operations to include a new site in ... produce packaging components for insulin injector cartridges and other ... from pharmaceutical and biotech customers. Once operational, this new ...
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... , BOSTON, Nov. 17 ... and information management solutions, today announced that it will showcase ... (IDNs) at the 2009 Radiological Society of North America (RSNA) ... IL. AMICAS will be in the North Hall in booth ...
... HistoRx today announced that the Company,s proprietary AQUA technology, ... was noted in a recent National Comprehensive Cancer ... testing in breast cancer as one of the "... promising ... PgR in breast cancer tissue." Experts from the country,s ...
Cached Medicine Technology:AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 2AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 3AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force 2
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... poses heightened risk, but it,s talked about by only ... -- Even though people with rheumatoid arthritis (RA) may ... rarely discussed with their doctors, says a U.S. study ... , The researchers, led by Betsy Sleath, of the ...
... of Preventive Medicine and Partnership for Prevention ... Killer -, WASHINGTON, Feb. 11 The ... Prevention (Partnership) have joined,forces to change the way ... cost-effective disease prevention. The organizations,have targeted heart disease, ...
... PRINCETON, N.J., Feb. 11 New Jersey,s,hospitals would lose ... total,of $2.9 billion through 2013 if President Bush,s proposed ... by the New Jersey,Hospital Association., The cuts are ... last week. All told, the budget plan calls for ...
... HealthPartners first Minnesota health care organization to measure ... BLOOMINGTON, Minn., Feb. 11 HealthPartners,today released a ... different racial/ethnic backgrounds receiving certain types of,care in ... exist and,examples of improvements it is making to ...
... Women,s Cancer, Theme, Spotlights Four Decades of ... CHICAGO, Feb. 11 The Society of Gynecologic,Oncologists ... Women,s Cancer March,9-12 at the Tampa Convention Center ... more than 350 scientific presentations,lectures, workshops, symposium, surgical ...
... of UPMC have identified a key protein target that may ... to prevent and new therapies to treat pneumonia, the leading ... Kolls, MD, chief of the Division of Pediatric Pulmonary Medicine, ... the importance of a protein known as interleukin 22 (IL-22) ...
Cached Medicine News:Health News:Depression Rarely Discussed With RA Patients 2Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 2Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 3Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 4Health News:Bush Budget Cuts Total $2.9 Billion for N.J. Hospitals 2Health News:New Report Identifies Health Disparities and Reduction Strategies 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 3Health News:Children's Hospital scientists identify possible target for prevention and treatment of pneumonia 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: